Helped by expected favorable exchange rate movements over the rest of the fiscal year, and the strong first-half performance of prostate cancer drug Xtandi in the US, Astellas Pharma Inc. has raised its core sales and profit forecast for fiscal 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?